Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
1(11%)
Results Posted
80%(4 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_3
3
33%
Ph phase_1
4
44%
Ph early_phase_1
1
11%
Ph phase_2
1
11%

Phase Distribution

5

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(5)
Terminated(3)

Detailed Status

Completed5
Terminated3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
62.5%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 14 (44.4%)
Phase 21 (11.1%)
Phase 33 (33.3%)

Trials by Status

completed556%
terminated333%
active_not_recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
active_not_recruitingearly_phase_1

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

NCT05469009
terminatedphase_3

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

NCT05310071
terminatedphase_3

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

NCT04241068
completedphase_3

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

NCT05108922
completedphase_1

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

NCT05216887
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05469009Early Phase 1

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

Active Not Recruiting
NCT05310071Phase 3

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
NCT04241068Phase 3

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Terminated
NCT05108922Phase 3

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Completed
NCT05216887Phase 1

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

Completed
NCT04924140Phase 1

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

Completed
NCT03639987Phase 2

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

Terminated
NCT02434718Phase 1

Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease

Completed
NCT02782975Phase 1

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9